Harreiter, J., Just, I., Leutner, M., Bastian, M., Brath, H., Schelkshorn, C., Klepochova, R., Krššák, M., & Kautzky‐Willer, A. (2021). combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24‐week, prospective, randomized, placebo‐controlled pilot trial. Diabetes, obesity & metabolism, 23(5), 1129–1139. http://access.bl.uk/ark:/81055/vdc_100127528868.0x00001b